Lipocine Inc (LPCN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.53+6.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LPCN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | 3.7 | 2.0 | 11.2 | (2.9) | 0.5 | 16.1 | 0.0 | 0.2 | 0.4 | 0.0 | 0.0 |
| Total Revenues | 3.7 | 2.0 | 11.2 | (2.9) | 0.5 | 16.1 | 0.0 | 0.2 | 0.4 | 0.0 | 0.0 |
| Operating Expenses & Income | |||||||||||
| R&D Expenses | 9.6 | 8.6 | 7.4 | 10.2 | 8.6 | 7.7 | 9.7 | 7.5 | 6.5 | 11.0 | 8.1 |
| Other Operating Expenses, Total | — | — | — | — | — | — | — | — | — | 0.2 | 0.2 |
| Operating Income | (10.1) | (10.4) | (1.2) | (17.9) | (12.1) | 3.1 | (18.0) | (12.9) | (11.3) | (21.2) | (19.2) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | — | — | — | 0.0 | 0.2 | 0.4 | 0.8 | — | — | — |
| Interest & Investment Income | 0.7 | 0.7 | 1.1 | 1.4 | 0.6 | 0.1 | 0.1 | 0.4 | — | — | — |
| Net Interest Expenses | — | — | — | — | — | — | 0.3 | 0.3 | — | — | — |
| Other Non-Operating Income / Expenses | 0.7 | 0.7 | 1.2 | 1.6 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (9.3) | (9.6) | 0.0 | (16.4) | (10.8) | (0.6) | (21.0) | (13.0) | (11.7) | (21.0) | (19.0) |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||
| Net Income | (9.3) | (9.6) | 0.0 | (16.4) | (10.8) | (0.6) | (21.0) | (13.0) | (11.7) | (21.0) | (19.0) |
| Per Share | |||||||||||
| Basic EPS | (1.13) | (1.77) | — | (3.10) | (0.12) | (0.01) | (0.38) | (0.50) | (0.55) | (1.05) | (1.04) |
| Diluted EPS | (1.13) | (1.69) | — | (3.14) | (0.13) | (0.01) | (0.38) | (0.50) | (0.55) | (1.05) | (1.04) |
| Revenue per Share | 0.45 | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 8.2 | 5.4 | 5.3 | 5.3 | 88.5 | 86.9 | 55.7 | 25.9 | 21.4 | 20.1 | 18.3 |
| Diluted Weighted Avg Shares | 8.2 | 5.7 | 5.4 | 5.3 | 88.9 | 86.9 | 55.7 | 25.9 | 21.4 | 20.1 | 18.3 |
| Supplemental | |||||||||||
| EBITDA | — | (10.3) | (1.1) | (17.9) | (12.1) | 3.1 | (18.0) | (12.9) | (11.3) | (21.2) | (19.2) |
| EBIT | (10.1) | (10.4) | (1.2) | (17.9) | (12.1) | 3.1 | (18.0) | (12.9) | (11.3) | (21.2) | (19.2) |
| Effective Tax Rate | — | — | — | — | — | — | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.